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Purpose: To analyze treatment outcome and side effects of adjuvant radiotherapy 
using radiotherapy fields and doses which have evolved over the last two decades in 
a single institution. Materials and Methods: Forty-one patients received radiother-
apy after orchiectomy from 1996 to 2007. At our institution, the treatment field for 
stage I seminoma has changed from dog-leg (DL) field prior to 2003 to paraaortic 
(PA) field after 2003. Fifteen patients were treated with the classic fractionation 
scheme of 25.5 Gy at 1.5 Gy per fraction. Other patients had been treated with mod-
ified schedules of 25.05 Gy at 1.67 Gy per fraction (n=15) and 25.2 Gy at 1.8 Gy 
per fraction (n=11). Results: With a median follow-up of 112 months, the 5-year 
and 10-year survival rates were 100% and 96%, respectively, and 5-year and 10-
year relapse-free survival rates were both 97.1%. No in-field recurrence occurred. 
Contralateral seminoma occurred in one patient 5 years after treatment. No grade 
III‒IV acute toxicity occurred. An increased rate of grade 1‒2 acute hematologic 
toxicity was found in patients with longer overall treatment times due to 1.5 Gy per 
fraction. The rate of grade 2 acute gastrointestinal toxicity was significantly higher 
with DL field than with PA field and also higher in the 1.8-Gy group than in the 1.5-
Gy and 1.67-Gy groups. Conclusion: Patients with stage I seminoma were safely 
treated with PA-only radiotherapy with no pelvic failure. Optimal fractionation 
schedule needs to be explored further in order to minimize treatment-related toxicity.
Key Words:   Testicular seminoma, para-aortic radiotherapy, late complication, 
secondary malignancy
INTRODUCTION
Testicular cancer is the most frequent germ cell tumor in men aged 15‒35 years. Its 
prevalence has been increasing annually up to 2% worldwide over the past 40 years,1,2 
and seminoma accounts for approximately one third of testicular cancer cases.3 In the 
treatment of early seminoma, adjuvant radiotherapy (RT), active surveillance, or che-
motherapy may be selected as treatment options after radical orchiectomy. Irrespec-
tive of treatment modality, the 5-year survival rate and disease-specific survival rate 
are more than 97% and 99‒100%, respectively, indicating a very high cure rate.4
Postoperative adjuvant radiotherapy has long been considered as a standard 
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cluded from this study. At the time of initial diagnosis, all pa-
tients underwent physical examination, hematologic testing 
for tumor markers, such as alpha-fetoprotein (AFP), beta-hu-
man choriogonadotropin (β-HCG), and lactate dehydroge-
nase (LDH), chest X-ray, ultrasonography, and abdominal 
pelvic CT.
The median age of the patients was 34 years (range 21‒56 
years). The main symptoms observed during the diagnosis 
included scrotal masses and swelling. Among the 41 pa-
tients, five patients (12%) had pain in addition to scrotal 
masses and swelling. Right testicular involvement was more 
frequently found. Eleven patients (27%) had a history of 
cryptorchidism. Increased LDH and beta-HCG were ob-
served in approximately one third of the patients, but in-
creased AFP was found in none of the patients.
Treatment
Radiotherapy was conducted using a linear accelerator, with 
10-MV photon delivered in anteroposterior and posteroan-
terior apposing fields. At our institution, the DL field (Fig. 
1A) had been used prior to 2003, while the PA field (Fig. 
1B) has been mainly used in more recent years. In the cur-
rent study, 26 patients were treated with DL field and 15 pa-
tients with PA field (Table 1). The margin of the radiation 
field for the PA field was defined as the superior border of 
the T11 vertebrate and the inferior border of the L5 verte-
brate. For the DL field, the inferior border was the top of 
the obturator foramen, and the lateral field included the tips 
of the transverse process of the lumbar vertebra. For left-
sided tumors, the lateral field was widened to include the 
left renal hilar nodes. If patients had a left testicular tumor, 
their left renal hilum was also included. A clamshell was 
used for the protection of the opposite testis upon treatment. 
Radiotherapy with three fractionation schedules was con-
ducted according to the physician’s preference: 15 patients 
received total 25.5 Gy at a daily dose of 1.5 Gy per frac-
tion, 15 patients received total 25.05 Gy at 1.67 Gy per 
fraction, and 11 patients received total 25.2 Gy at 1.8 Gy 
per fraction. The median treatment period of radiotherapy 
was 23 days (range 21‒27 days) for fractional doses of 1.5 
Gy, 19 days (range 17‒23 days) for 1.67 Gy, and 19 days 
(range 13‒22 days) for 1.8 Gy. 
Follow-up and statistical analysis
Patients were followed every 6 months for two years after 
radiotherapy and every year thereafter. The patients were ex-
amined clinically at each follow-up, blood tests and a chest 
treatment option for early testicular seminoma. However, al-
ternative treatment options, such as surveillance and single-
drug chemotherapy, have recently been conducted to replace 
adjuvant radiotherapy.5,6 Researchers who support surveil-
lance without postoperative adjuvant therapy claim that no 
significant difference in overall survival (OS) is found be-
tween surveillance and adjuvant therapy, given that the rate 
of successful salvage treatment via radiotherapy or chemo-
therapy is high in case of recurrence. However, compared to 
the recurrence rate of 3‒5% after adjuvant radiotherapy, sur-
veillance resulted in a higher recurrence rate of 15‒20%, 
which may increase economic burden and anxiety among 
patients.7 Postoperative carboplatin chemotherapy was re-
ported to have treatment efficacy comparable to that of ra-
diotherapy.6 However, only short-term follow-up data is 
available for carboplatin-based chemotherapy, and one must 
justify administering systemic treatment for a disease of 
which most common pattern of failure is local recurrence.
Meanwhile, acute and chronic complications caused by ra-
diotherapy have been significantly reduced over the past 20 
years by reducing radiation field and total dose while main-
taining a high cure rate. The radiation field has changed from 
treating the lymph nodes both in the mediastinum and below 
diaphragm to treating only the lymph nodes below the dia-
phragm. More recently, the radiation field has been further 
reduced from the traditional dog-leg (DL) field, which in-
cludes the ipsilateral pelvic lymph nodes and aortic lymph 
nodes, to the paraaortic (PA) field, which includes the aortic 
lymph nodes only.8 Radiation dose has also been gradually 
reduced from 40‒50 Gy to 20‒25 Gy.9
This study was conducted to investigate the outcomes of 
adjuvant radiotherapy for stage I testicular seminoma and 
to analyze the impact of evolution of radiotherapy field and 
fractionation schemes over the last two decades on treat-
ment-related toxicity. 
MATERIALS AND METHODS
Patients
This study was retrospectively conducted on 41 patients who 
underwent radiotherapy after orchiectomy for stage I testicu-
lar seminoma from 1996 to 2007. The study was approved 
by the Institutional Review Board of our institution (4-2012-
0821). Those who had a previous history of other malignant 
tumors or who had previous radiotherapy or chemotherapy 
before being diagnosed with testicular seminoma were ex-
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ty occurred in 22 patients (54%); of these patients grade 1 
and grade 2 leukopenia occurred in 14 patients (34%) and 8 
patients (20%). Only one patient who had grade 1 leukope-
nia experienced thrombocytopenia, and no patient experi-
enced anemia. As for gastrointestinal (GI) toxicity, grade 
1‒2 nausea occurred, but no other symptom was found.
Radiotherapy-associated acute toxicity was further ana-
lyzed according to radiation field and fractionation scheme 
(Table 2). The frequency of grade 1‒2 leukopenia and nau-
sea requiring anti-emetics (grade 2) was set as a determinant 
for radiotherapy toxicity. In the analysis of the correlation of 
radiation field with hematologic toxicity using Spearman’s 
rho, the increase in the rate of grade 1‒2 hematologic toxic-
ity was more significant in the DL field group (65%) than 
in the PA field group (33%) (p=0.049). As for the fraction-
ation scheme, increased toxicity was significant in the 1.5-
Gy group (87%), whose overall treatment time for radio-
therapy was approximately one week longer, compared 
with 1.67-Gy (33%) and 1.8-Gy (36%) groups (grade 1‒2 
toxicity, p=0.010). When a partial correlation was examined 
by excluding the interaction of these two factors, a statistical 
significance was only found for fractionation scheme (p= 
0.007). When the radiation field and fractionation schemes 
were compared with the incidence of upper GI toxicity re-
quiring anti-emetics using Spearman’s rho, no significant 
difference in toxicity was found between the PA field group 
and the DL field group (p=0.161), but the toxicity signifi-
cantly increased in the 1.8-Gy group, to the extent that anti-
emetics were required in all the patients treated with 1.8 Gy 
X-ray were obtained, and abdominal pelvic CT was conduct-
ed. Toxicity was evaluated using the Radiation Therapy On-
cology Group toxicity criteria. Treatment-related adverse 
events occurring 6 months after completion of treatment 
were considered as late toxicity. The relationship of radia-
tion field and dose with adverse events was examined using 
Spearman’s rho. The survival period of the patients was ob-
tained using the Kaplan-Meier method. Significance was 
defined as p-values of less than 0.05.
 
RESULTS
 
Survival and patterns of failure
The median follow-up period was 112 months (range 50‒ 
200 months). The 5-year and 10-year OS rates of the total 
patients were 100% and 96.0%, respectively (Fig. 2A). Dur-
ing the follow-up period, one patient died of intercurrent 
disease 83 months after radiotherapy. The 5-year and 10-
year relapse-free survival (RFS) rates of the total patients 
were both 97.1% (Fig. 2B). No recurrence was found with-
in the radiation field. However, seminoma was found in the 
opposite testis in one patient 57 months after radiotherapy; 
the patient underwent salvage orchiectomy and was report-
ed after 10 years to be free of disease.
Toxicity
During radiotherapy and the follow-up period, no grade 3‒4 
acute toxicity was observed. Grade 1‒2 hematologic toxici-
Fig. 1.  (A) Dog-leg field and (B) paraaortic field.
A B
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1.67 Gy per fraction showed the best toxicity profile for 
both hematologic toxicity and GI disorders.
No chronic complication that was directly associated with 
radiotherapy occurred during the follow-up period; howev-
er, acute myeloid leukemia (AML; M3) occurred in one pa-
tient 80 months after radiotherapy.
DISCUSSION
At our institution, the results of adjuvant radiotherapy after 
surgical treatment for early testicular seminoma were excel-
per fraction (p=0.002). Interestingly, when a partial correla-
tion was examined by excluding the interaction between 
RT field and fractionation scheme, a statistical significance 
was found for both RT field (p=0.035) and fractionation 
scheme (p=0.001). In summary, an increase in hematologic 
toxicity depended more on the fractionation scheme, partic-
ularly in the case of the 1.5-Gy group, than on the RT field. 
As for GI disorders requiring anti-emetics, toxicity was af-
fected by both RT field and fractionation scheme, increas-
ing more in the DL field group than in the PA field group 
and more in the 1.8-Gy group than in the 1.5-Gy and 1.67-
Gy groups. Thus, among the three fractionation schemes, 
Table 1. Patient & Treatment Characteristics
Total patients (n=41) Paraaortic field (PA) (n=15) Dog-leg field (DL) (n=26)
No. of patients % No. of patients % No. of patients %
Age
    20‒29 14 34 5 33 9 35
    30‒39 18 44 7 47 11 42
    40‒49   6 15 1 7 5 19
    50‒59   3 7 2 13 1 4
    Total 41 100 15 100 26 100
Symptoms
    Swelling 15 32 7 41 8 27
    Tenderness   5 11 2 12 3 10
    Mass 27 57 8 47 19 63
Involved side
    Left 13 32 4 27 9 35
    Right 28 68 11 73 17 65
    Total 41 100 15 100 26 100
Tumor size
    ≤4 cm   6 15 2 13 4 15
    >4 cm 35 85 13 87 22 85
Previous  history
    Inguinal herniorrhaphy   5 12 2 13 3 12
    Cryptorchidism 11 27 4 27 7 27
    Vasectomy   1 2 0 0 1 4
Preoperative tumor markers
  (elevated)
    LDH 14 34 8 53 6 23
    Beta-HCG 15 37 5 33 10 38
    AFP   0 0 0 0 0 0
T-Stage 
    T1 35 85 12 80 23 88
    T2   6 15 3 20 3 12
Vascular/lymphatic permeation
    No 35 85 13 87 23 85
    Yes   6 15 2 13 4 15
Fraction size/total dose
    150/2550 cGy 15 36 1 7 14 54
    167/2505 cGy 15 36 13 86 2 8
    180/2520 cGy 11 28 1 7 10 38
LDH, lactate dehydrogenase; HCG, human choriogonadotropin; AFP, alpha-feto protein. 
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the alternative treatment regimens should be re-evaluated 
based on the treatment outcomes and adverse events of 
modern radiotherapy.
The occurrence of secondary malignancy is an important 
issue among treatment-related chronic complications. In the 
current study, AML occurred only in one patient 80 months 
after radiotherapy. Due to the limited statistical power, it was 
difficult to confirm any direct correlation of AML with the 
radiotherapy. However, as secondary malignancies may oc-
cur due to genetic predisposition, immunodeficiency, com-
mon carcinogenic influences, and other environmental fac-
tors, it is important to accurately investigate the interaction 
of these factors with radiotherapy.12 For example, in the ear-
ly era of Hodgkin’s lymphoma treatment, radiation was de-
livered to a large field including entire lymph nodes in both 
sides of the diaphragm, at a dose of up to 40‒50 Gy. How-
ever, in the current treatment of Hodgkin’s lymphoma, the 
treatment field is gradually reduced to involved-field or in-
volved-nodal areas, and radiation is delivered at a decreased 
dose of 20‒30 Gy.13 A recent study reported that radiation 
treatment for Hodgkin’s lymphoma with reduced field size 
lent: the 10-year OS rate was 96.0%, and the RFS rate was 
97.1%, with no recurrence except for seminoma that oc-
curred in the contralateral testis. Potential causes of contra-
lateral testicular seminoma consist of de novo metachro-
nous primary malignancy, recurrence due to the metastasis of 
the primary lesion, and secondary malignancy due to radia-
tion scattering. In a multi-institutional study conducted by 
Kamba, et al.,10 the recurrence rate of contralateral testis was 
similar between the surveillance (21.1%) and RT (22.2%) 
groups. Considering the aforementioned result, it is likely 
that contralateral testicular seminoma is attributable to de 
novo metachronous primary malignancy.
Rationale for active surveillance or single-agent chemo-
therapy after orchiectomy is the assumption that radiothera-
py causes significant toxicity, in particular, increased rate of 
second malignancy, which may be attributed to the results of 
previous studies involving large-field and higher-dose radio-
therapy. Modern radiotherapy schemes do not cause the ad-
verse events observed in the previous treatments and mini-
mize treatment-associated toxicity by significantly reducing 
radiation dose and treatment field.11 Thus, the rationale for 
Table 2. Acute Toxicities according to Radiotherapy Volume and Fraction Size
Hematologic toxicity grade p value for correlation Upper GI toxicity requiring anti-emetics p value for correlation
0 (%) 1 (%) 2 (%) Spearman’s rho Partial No (%) Yes (%) Spearman’s rho Partial
RT field 0.049 0.090 0.161 0.035 
    PA alone 10 (67)   2 (13)   3 (20)   8 (53)   7 (47)
    Dog-leg   9 (35) 12 (46)   5 (19)   8 (31) 18 (69)
Fractionation (Fr 
  size/total dose, Gy)
0.010 0.007 0.002 0.001 
    1.5/25.5   2 (13)   9 (60)   4 (27)   9 (60)   6 (40)
    1.67/25.05 10 (67)   2 (13)   3 (20)   7 (47)   8 (53)
    1.8/25.2   7 (64)   3 (27) 1 (9) 0 (0)   11 (100)
RT, radiotherapy; PA, paraaortic.
Fig. 2. (A) Overall survival rate and (B) relapse-free survival rate of all patients.
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lignancy, resulting in a high salvage rate via orchiectomy, 
systemic chemotherapy may not be a suitable option for the 
prevention of contralateral testicular seminoma, which has 
a recurrence rate of only 2%.
The current study is meaningful in that it was conducted 
on the patients who underwent standardized radiotherapy 
with a long term follow-up at a single institution, and that 
acute and chronic adverse events were analyzed in detail in 
relation to radiation field and dose. As for acute toxicity, 
many studies reported that no severe adverse events except 
for mild toxicity occurred after modern radiotherapy.9,17 
Among studies that have been conducted to determine the 
minimum radiation field and total dose that can effectively 
reduce toxicity in the radiotherapy of testicular seminoma, 
Medical Research Council TE18 and European Organiza-
tion for Research and Treatment of Cancer Trial 30942 
showed that a total dose of 20 Gy irradiated to patients for 
two weeks resulted in the same treatment outcomes, mild 
acute toxicity, and no late complications.9 In the current 
study, most of the patients underwent radiotherapy at a con-
sistent dose of 25 Gy, and no acute toxicity related to radio-
therapy occurred except for grade 1‒2 leukopenia and nau-
sea. Furthermore, no chronic complications directly asso-
ciated with radiotherapy (e.g., gastric ulcer) occurred.  
In the analysis of toxicity associated with three fraction-
ation schemes, grade 1‒2 leukopenia significantly increased 
in the group that received a lowest fractional dose of 1.5 Gy 
(p=0.007). The occurrence rate of leukopenia was signifi-
cantly higher in the 1.5-Gy group than in the 1.67-Gy and 
1.8-Gy groups. This was likely to have occurred, given that 
the median treatment period was 23 days (range 21‒27 
days) in the 1.5-Gy group, longer than 19 days (range 17‒23 
days) in the 1.67-Gy group, and 19 days (range 13‒22 days) 
in the 1.8-Gy group, and that leukopenia was more likely to 
have been detected from blood tests obtained from a longer 
treatment period. However, all of the patients with grade 
1‒2 leukopenia in the current study recovered spontaneous-
ly without bone marrow rescue injection. In the analysis for 
the correlation of fractionation schedule and GI toxicity, 
both Spearman’s rho and partial correlation showed that 
toxicity significantly increased in the 1.8-Gy group. This re-
sult is consistent with the result of a previous study reporting 
that acute toxicity such as nausea increased as the fraction 
size increased in radiotherapy. In the current study, one third 
of the patients received a total dose of 25 Gy in 1.67 Gy per 
fraction over 3-week period. This fractionation schedule can 
shorten the overall treatment time compared to a 1.5-Gy-
and radiation dose resulted in no additional risk of second-
ary malignancy. In a comparative study that was conducted 
on the largest number of patients with Hodgkin’s lympho-
ma, Koshy, et al.14 reported that no additional secondary 
malignancy was observed among patients who underwent a 
combination treatment of chemotherapy and radiotherapy 
in comparison with patients who were treated with chemo-
therapy alone. This finding suggests that radiotherapy does 
not cause secondary malignancy except for those that occur 
due to chemotherapy for the treatment of Hodgkin’s lym-
phoma. In a similar manner, accurate evaluation of adverse 
events is required for the recently standardized treatment of 
seminoma, such as infradiaphragmatic and PA field irradia-
tion and radiation doses of less than 30 Gy.
Alternative treatment modalities also have limitations. At 
our institution, 13 patients were followed who had received 
orchiectomy between 1996 and 2007 without receiving ad-
juvant radiotherapy: 4 patients after chemotherapy and 9 
patients without chemotherapy. The median follow up for 
these patients was 62 months (range 19‒138 months). One 
patient who was followed without adjuvant treatment expe-
rienced regional recurrence 18 months after orchiectomy 
and was 33-month disease-free after salvage chemotherapy 
at the time of writing. Among the 4 patients who were treat-
ed with chemotherapy, grade 3 leukopenia was observed in 
2 patients and grade 1 leukopenia in 1 patient; however, 
toxicity could not be evaluated in a patient who had re-
ceived chemotherapy overseas. A high recurrence rate of 
15‒20% after active surveillance is alarming despite the ex-
pectation that high cure rates can be achieved with salvage 
treatment.7 In addition, the late-relapsing characteristic of 
testicular seminoma contributes to several disadvantages of 
active surveillance such as increased economic burden at-
tributable to long-term follow-ups via annual CT examina-
tion, concerns about radiation exposure due to multiple CT 
scans in young patients, and long-term anxiety in both pa-
tient and doctor. In the case of chemotherapy, the follow-up 
period is still insufficient to analyze the rate of late recur-
rence and the occurrence of chemotherapy-induced second-
ary malignancy.6 The result of a recent study showed that 
testicular intraepithelial neoplasia still persisted after ad-
ministration of chemotherapy in patients who were diag-
nosed with testicular intraepithelial neoplasia in a testicular 
biopsy.15 Chemotherapy seems to delay the occurrence of 
contralateral testicular seminoma rather than preventing it.16 
Considering the possibility that contralateral testicular sem-
inoma may occur as a de novo metachronous primary ma-
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search and Treatment of Cancer Trial 30942 (ISRCTN18525328). 
J Clin Oncol 2005;23:1200-8.
10. Kamba T, Kamoto T, Okubo K, Teramukai S, Kakehi Y, Matsuda 
T, et al. Outcome of different post-orchiectomy management for 
stage I seminoma: Japanese multi-institutional study including 
425 patients. Int J Urol 2010;17:980-7.
11. Mead GM, Fossa SD, Oliver RT, Joffe JK, Huddart RA, Roberts 
JT, et al. Randomized trials in 2466 patients with stage I semino-
ma: patterns of relapse and follow-up. J Natl Cancer Inst 2011; 
103:241-9.
12. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen 
FE, et al. Risk of second malignant neoplasms among long-term 
survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
13. Girinsky T, Ghalibafian M. Radiotherapy of hodgkin lymphoma: 
indications, new fields, and techniques. Semin Radiat Oncol 2007; 
17:206-22.
14. Koshy M, Rich SE, Mahmood U, Kwok Y. Declining use of ra-
diotherapy in stage I and II Hodgkin’s disease and its effect on 
survival and secondary malignancies. Int J Radiat Oncol Biol 
Phys 2012;82:619-25.
15. Kleinschmidt K, Dieckmann KP, Georgiew A, Loy V, Weissbach 
L. Chemotherapy is of limited efficacy in the control of contralat-
eral testicular intraepithelial neoplasia in patients with testicular 
germ cell cancer. Oncology 2009;77:33-9.
16. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T. 
The long-term risks of adjuvant carboplatin treatment for stage I 
seminoma of the testis. Ann Oncol 2008;19:443-7.
17. Fosså SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hod-
son NJ, et al. Optimal planning target volume for stage I testicular 
seminoma: a Medical Research Council randomized trial. Medical 
Research Council Testicular Tumor Working Group. J Clin Oncol 
1999;17:1146.
18. Gordon W Jr, Siegmund K, Stanisic TH, McKnight B, Harris IT, 
Carroll PR, et al. A study of reproductive function in patients with 
seminoma treated with radiotherapy and orchidectomy: (SWOG-
8711). Southwest Oncology Group. Int J Radiat Oncol Biol Phys 
1997;38:83-94.
per-fraction schedule and reduce acute toxicity compared to 
a 1.8-Gy-per-fraction schedule. However, further study is 
required to determine optimal dose, treatment duration, and 
total dose for early testicular seminoma based on the results 
of the current study. 
Although there have been controversies over the use of 
dog-leg field and PA field, more centers have accepted the 
PA field.8,17 The PA field has been used at our institution 
since 2003. Although the PA field has a relatively short fol-
low-up period compared to the DL field, no pelvic recur-
rence occurred in the current study. In the analysis of acute 
toxicity, an increased rate of GI toxicity such as nausea was 
observed in the DL field group compared to the PA field 
group. Thus, the PA field can be considered as a safe and 
effective field for early testicular seminoma.
One limitation of this study was that most of the patients 
did not undergo semen analysis before and after radiothera-
py. Thus, information regarding late radiation-induced 
complications such as reduced sperm production and infer-
tility was not available. In a Southwest Oncology Group 
study (SWOG-8711) that was conducted to investigate re-
productive function in 207 patients with testicular semino-
ma after radiotherapy, sperm concentration returned to nor-
mal levels within one year after radiotherapy in the patients 
who underwent radiotherapy at a testicular dose of <0.8 Gy 
and used clamshell-type shields for maximum protection.18 
In this study, most of the patients were young males, and a 
clamshell-type shield was used in the opposite testis for the 
prevention of infertility during the treatment.
The result of this single-institution study showed that pa-
tients with stage I seminoma could be safely treated with 
PA-only radiotherapy with no pelvic failure after a median 
follow-up of 10 years. Optimal fraction schedule to mini-
mize acute and chronic toxicity needs to be explored further.
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